Description

Treczimus

Composition:

Each gram of ointment contains:

Tacrolimus 0.03 mg

Properties:

Tacrolimus belongs to the group of calcineurin inhibitors. It binds to a specific cytoplasmic protein immunophilin (FKBP12), which is the cytosolic receptor for calcineurin (FK506). As a result, a complex is formed that includes tacrolimus, FKBPI2, calcium, calmodulin and calcineurin, which leads to inhibition of the phosphatase activity of calcineurin. This makes it impossible for dephosphorylation and translocation of the nuclear factor of activated T cells (NFAT), which is necessary for the initiation of transcription of genes encoding the production of cytokines, key for the T-cell immune response (IL-2 and interferon-gamma). In addition, tacrolimus inhibits the transcription of genes encoding the production of cytokines such as IL-3, IL-4, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor (TNFα), which are involved in the initial stages of T activation. – lymphocytes. In addition, under the influence of tacrolimus, the release of inflammatory mediators from mast cells, basophils and eosinophils is inhibited, as well as a decrease in the expression of FcεRI (high-affinity surface receptor for immunoglobulin E) on Langerhans cells, which leads to a decrease in their activity and antigen presentation to T-lymphocytes. tacrolimus does not affect collagen synthesis and thus does not cause skin atrophy.

Indications:

treatment of atopic dermatitis (of moderate severity and severe forms) in case of its resistance to other means of external therapy or the presence of contraindications to such.

In adults and children over 2 years old, Treximus ointment is used in the form of 0.03% ointment.

Method of administration and dosage:

For adults and children over 2 years of age, Treximus is applied in a thin layer to the affected skin. The drug should not be applied to mucous membranes and under occlusive dressings.

Use in children (2 years of age and older) and adolescents under 16 years of age:

Treatment should begin with the application of 0.03% ointment 2 times / day. The duration of treatment according to this scheme should not exceed 3 weeks. In the future, the frequency of use is reduced to 1 time / day, the treatment continues until the lesions are completely cleared.

Use in adults and adolescents 16 years of age and older:

Treatment should begin with the use of 0.1% Treximus ointment 2 times / day and continue until the lesions are completely cleared.

Contraindications:

– serious violations of the epidermal barrier, in particular, Netherton’s syndrome, lamellar ichthyosis, skin manifestations of the graft versus host reaction, as well as generalized erythroderma (due to the risk of increased systemic absorption of tacrolimus);

-Children up to 2 years old (for 0.03% ointment);

– children and adolescents up to 16 years old (for 0.1% ointment);

-pregnancy;

-the period of breastfeeding;

-increased sensitivity to tacrolimus, auxiliary components of the drug, macrolides.

Precautionary measures:

During the application of the ointment, it is necessary to avoid contact with the sun’s rays, visiting a solarium, therapy with ultraviolet B or A rays in combination with psoralen (PUVA therapy).

Treximus should not be used to treat lesions that are considered potentially malignant or precancerous.

Do not use emollients for 2 hours on the areas of the skin to which the drug was applied.

Side effects:

Infectious diseases: often – local skin infections, regardless of etiology (in particular, but not limited to those listed, Kaposi’s herpetic eczema, folliculitis, infection caused by the Herpes simplex virus, other infections caused by viruses of the Herpes viridae family).

From the side of metabolism and nutrition: often – alcohol intolerance (flushing of the face or symptoms of skin irritation after drinking alcohol).

From the nervous system: often – paresthesia, hyperesthesia.

Skin and subcutaneous tissue disorders: often – folliculitis, itching; infrequently – acne.

General disorders and disorders at the injection site: very often – burning and itching in the area of ​​application.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains a tube of 20 grams, paper instructions.